Enhancing Immune Response with Probiotics
81 patents in this list
Updated:
Enhancing immune response has become a focal point of health and wellness, and probiotics are emerging as a powerful ally in this endeavor. These beneficial microorganisms play a crucial role in supporting and strengthening the body's natural defenses.
This article delves into the science behind probiotics and their impact on the immune system. By promoting a healthy gut microbiome, probiotics contribute to a robust immune response, helping to ward off infections and maintain overall health.
As research continues to uncover the myriad benefits of probiotics, we can better understand how to harness their potential for improved immune function and well-being.
1. Amplifying a patient's lung microbiome for personalized medicine applications
UNIVERSITY OF SOUTH FLORIDA, 2023
Obtaining and amplifying a patient's lung microbiome for personalized medicine applications like prognosis, antibiotic testing, and transplantation. The method involves culturing bronchoalveolar lavage samples in specific media to expand the lung bacteria populations.
2. Antiviral probiotic that can effectively treat viral infections
TOHOKU UNIVERSITY, 2023
An antiviral probiotic that can effectively prevent and treat viral infections. The probiotic contains strains of Lactobacillus bacteria that have been selected for their ability to enhance expression of antiviral factors and reduce expression of factors that inhibit antiviral activity. The strains also have 16S rRNA gene sequences similar to the selected strains. Administering these probiotic strains can boost the body's natural antiviral defenses and provide protection against viral infections, including combined viral and bacterial infections.
3. Compositions and formulations containing live microbial populations isolated from plants
Solarea Bio, Inc., 2023
Compositions and formulations containing live microbial populations isolated from plants that can be used to treat and/or prevent immune system disorders, and conditions related to inflammation. The compositions can be in the form of pharmaceutical compositions, medical foods, dietary supplements, or solid food stuffs. The formulations can contain specific plant-derived bacterial and fungal species that can reduce inflammation when ingested.
4. Recombinant microbes with reduced colonization properties
Wisconsin Alumni Research Foundation, 2023
Recombinant microbes with reduced colonization properties for use as therapeutic delivery vehicles. The microbes have reduced expression/activity of proteins involved in adhesion to host tissues. This reduces the risk of the therapeutic microbes colonizing the body after delivery and causing unintended effects. The modification involves reducing sortase, fibronectin-binding proteins, autolysins, surface-layer proteins, and other factors that promote adherence.
5. Preventing COVID-19
QUORUM INNOVATIONS, LLC, 2023
A composition for treating and preventing viral infections like COVID-19. The composition contains extracts of a bacterial strain called Lactobacillus fermentum Qi6 grown in biofilm form. The extracts inhibit viral entry and spread by modulating the immune system and potentially binding to viral receptors. The extracts also have potential antiviral proteins.
6. Inducing proliferation of T helper 17 cells in the gut
RIKEN, 2023
A bacterial composition that can be used as a pharmaceutical, adjuvant, or food ingredient to induce proliferation of T helper 17 (Th17) cells in the gut. The composition comprises certain species of human-derived bacteria or their culture supernatants that have been shown to strongly induce Th17 cells. These bacteria can be isolated from fecal samples and cultured. Administering the bacterial composition can promote immune function and help prevent or treat diseases that benefit from a Th17 response, such as infectious diseases.
7. Combination therapy for respiratory infections
UNIVERSITÉ DE TOURS, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), 2023
Combination therapy for respiratory infections that uses immunomodulatory agents and binding agents like antibodies. The combination involves administering an agent that can bind to the infectious pathogen, like an antibody, along with an immunomodulatory agent like a probiotic. The binding agent targets and neutralizes the pathogen, while the immunomodulatory agent enhances the immune response against it. Administering the binding agent by inhalation targets the respiratory infection.
8. Detecting pathogen exposure and treating the patient via analysis of the patient's microbio
Sun Genomics, Inc., 2023
Detecting exposure of a patient to an infectious pathogen and treating the patient via analysis and classification of the patient's microbiome. The method involves detecting exposure to a pathogen, analyzing the patient's microbiome to identify opportunistic pathogens indicating disease onset/recovery, and treating the patient with a customized therapeutic composition based on the microbiome analysis.
9. Oral compositions containing lactoferrin and probiotic bacteria for treating respiratory viral
SOFAR S.P.A., 2023
Oral compositions containing lactoferrin, probiotic bacteria, and other ingredients for treating respiratory viral infections like COVID-19. The compositions can include lactoferrin derivatives, Lactobacillus paracasei bacteria, N-acetylcysteine, and hyaluronic acid. The lactoferrin and bacteria boost antiviral immunity and inhibit virus replication.
10. Bifidobacterium animalis enhances survival and reduces lung pathology in
Huazhong Agricultural University, 2023
Using Bifidobacterium animalis to treat and prevent avian influenza virus infections. The Bifidobacterium animalis probiotic enhances survival and reduces lung pathology when given orally to mice infected with H7N9 avian influenza.
11. Prophylactic or therapeutic treatment of lower respiratory tract viral infections
BLIS TECHNOLOGIES LIMITED, 2023
Prophylactic or therapeutic treatment of lower respiratory tract (LRT) viral infections, particularly coronaviruses, using BLIS-producing Streptococcus salivarius strains and extracts thereof. The BLIS product inhibits the growth of LRT viruses, including SARS-CoV-2, and can be used to prevent or treat LRT virus infections. The treatment involves administering an effective amount of the BLIS product like S. salivarius strain Glasgow3.
12. Recombinant bacteria that produce lactate in vivo for treating autoimmune and
Synlogic Operating Company, Inc., The Brigham and Women's Hospital, Inc., 2023
Recombinant bacteria that produce D-lactate and/or L-lactate in vivo for treating autoimmune and inflammatory diseases. The bacteria are engineered to contain inducible lactate production genes that are activated in the low-oxygen gut environment. Administering the engineered bacteria to patients increases lactate levels, which then reduce inflammation and treat diseases like multiple sclerosis and colitis.
13. Promoting anti-inflammatory IL-10 production
MEIJI CO., LTD., 2023
Composition containing a combination of lactic acid bacteria and fermented milk that promotes the production of interleukin-10 (IL-10) while inhibiting production of interleukin-12 (IL-12). The composition has improved ability to promote anti-inflammatory IL-10 production compared to using lactic acid bacteria or fermented milk alone.
14. Leveraging bacteria to degrade host glycans and inhibit viral infections
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, 2023
Leveraging glycosidases and sulfatases produced by bacteria to degrade host glycans and inhibit viral infections. The bacteria Bacteroides thetaiotaomicron and Bacteroides ovatus, common members of the human gut microbiota, can degrade heparan sulfate (HS), a host glycan essential for viral entry. The abundance of B. thetaiotaomicron and B. ovatus decreased in COVID-19 patients, suggesting a potential link between microbiome composition and SARS-CoV-2 infectivity. Administering HS-degrading enzymes or bacteria to degrade HS on host cells could reduce viral binding and infection.
15. Modulate the immune system and reduce the risk of infections
SYNBALANCE SRL, 2023
A probiotic combination containing specific strains of Lactobacillus and Bifidobacterium bacteria to modulate the immune system and reduce the risk of infections in adults and elderly, especially seasonal infections like flu. The combination includes Lactobacillus plantarum and Bifidobacterium lactis along with other strains of Lactobacillus and Bifidobacterium.
16. Evaluating and reducing mosquito-attractiveness of an individual
Tata Consultancy Services Limited, 2023
Evaluating and reducing mosquito-attractiveness of an individual. It involves collecting a skin sample, sequencing the skin microbiome, analyzing the microbial composition, normalizing the data, and using a classifier to compute a mosquito attractiveness score. The score compares to a threshold to categorize as highly or poorly attractive. If highly attractive, skin microbe interventions are administered to reduce attractiveness.
17. Preventing infectious diseases in animals
Institut national de recherche pour I'agriculture, I'alimentation et I'environnement, ECOLE NATIONALE VETERINAIRE D'ALFORT, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, Biologicke Centrum AV CR v. v. i., 2023
Using an E. coli strain expressing high levels of the sugar molecule alpha-Galactose (alpha-Gal) as a feed additive, probiotic or oral vaccine to prevent or reduce infectious diseases in animals caused by pathogens that express alpha-Gal on their surface. The E. coli strain is used in non-human animals, like fish and poultry, that do not naturally produce alpha-Gal. Administering the alpha-Gal-rich E. coli strain stimulates an immune response to alpha-Gal, which then provides cross-protection against pathogens expressing alpha-Gal.
18. Vaccine platform using Lactobacillus as a vaccine platform to induce an immune
NORTH CAROLINA STATE UNIVERSITY, COLORADO STATE UNIVERSITY RESEARCH FOUNDATION, 2023
Engineered bacteria, such as Lactobacillus, as a vaccine platform to express immunogenic viral peptides to induce an immune response against pathogenic organisms like coronaviruses. The recombinant bacteria are safe, well tolerated, and augment the immune response to achieve a therapeutic effect. The vaccine platform targets protease cleavage sites in viral spike proteins to prevent cleavage and reduce infectivity. It aims to induce mucosal IgA responses via oral delivery to prevent viral entry at mucosal surfaces, along with systemic immunity. This vaccine approach using genetically engineered bacteria provides an adaptable and accessible mucosal vaccination strategy that can be rapidly deployed against emerging pathogens like coronaviruses.
19. Preventing viral infectious diseases and respiratory diseases
MD HEALTHCARE INC., 2023
Composition containing vesicles derived from Lactobacillus paracasei to prevent, treat or alleviate viral infectious diseases and respiratory diseases. The vesicles can be administered orally, inhaled or topically via food, drugs, cosmetics to deliver the active ingredient to the lungs and respiratory system.
20. Enteric-coated granular composition containing purified bee venom me
CHUNG JIN BIOTECH CO., LTD., 2023
Enteric-coated granular composition containing purified bee venom melittin and lactic acid bacteria for oral administration to enhance the immune system and recover from kidney injury. The composition contains melittin derived from bee venom and lactic acid bacteria like Lactobacillus. The melittin is purified to contain 60-65% melittin. The enteric coating allows release in the intestine. It enhances the immune system by increasing cytotoxic T cells, helper T cells, and B cells, and recovering from kidney injury by reducing inflammatory cytokines and NGAL protein expression.
Request the full report with complete details of these
+61 patents for offline reading.